Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRT7041 in healthy participants for pain
NCT07289776Phase 1Recruiting
- Sponsor
- Grünenthal GmbH
- Start
- Jan 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GRT7041 in pain, sponsored by Grünenthal GmbH. Primary endpoints: Number of participants with Adverse Events at 8 weeks and Number of participants with Serious Adverse Events at 8 weeks. Started Jan 2026; status: recruiting.
02
Drugs
GRT7041
03
Conditions
pain
Beyond the preview
Go deeper on NCT07289776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07289776.